WEST ORANGE, NJ – Nikolaos Tezapsidis, PhD, of West Orange, is working to find a cure for Alzheimer's disease, a devastating brain disorder affecting a large population of the aging society. He is doing so through the work of biotech company Neurotez, Inc., which he founded in 2005.

To celebrate his company’s 10th anniversary and support The Alzheimer's Association, Greater New Jersey Chapter, Neurotez is holding an event called, “Have Fun Do Good,” on Nov. 13, starting at 6 p.m., at the Essex House, which is located at 525 Northfield Avenue. The event will support the charity, with 75 percent of the proceeds collected going straight to it. The public is invited to attend the event where they will dine on specially-prepared food and listen to and/or dance to live music. Tickets are available HERE.

“We are celebrating our 10th anniversary as a company and we thought the best way to do that is with a charity event to give back to the Alzheimer’s Association, said Nikolaos. “They are the first organization that funded and kick-started my career as an independent research investigator in the Alzheimer’s field in 1997. I had already been involved as a researcher in the field since 1994.”

Sign Up for West Orange Newsletter
Our newsletter delivers the local news that you can trust.

While Nikolaos Tezapsidis has been a researcher in the field for 21 years, his connection to the illness grew when his mother Katie was diagnosed with Dementia, and later passed away.

“I have personal experience on how devastating a brain disorder that changes your behavior and personality can be,” he said. “My mother, who died two years ago, was afflicted by dementia, most likely Alzheimer’s.”

Dementia is the clinical expression of a multitude of pathological aberrations in the Central Nervous System, according to the Neurotez website. The most common pathological substrate in the demented elderly is Alzheimer’s disease. This CNS disorder is affecting more than five million Americans, and 18 million patients worldwide. Current medications provide limited and symptomatic relieve. There is a huge unmet medical need for disease-modifying treatments that will slow or revert the pathological cascades leading to neurodegeneration, according to the site.

Right now, Neurotez is working on a “promising drug for Alzheimer’s disease,” according to Nikolaos. It is a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk.

“My personal commitment is to develop a cure for Alzheimer’s disease, no matter what this may cost,” said Nikolaos. “There is no plan B and those close to me know exactly what I mean by that.”

Nikolaos shared that his company’s immediate future plans involve identifying investors to support the clinical development and approval of Neurotez’s drug for Alzheimer’s disease.

He said that so far, these efforts were supported through the National Institutes of Health and the New Jersey Commission of Science and Technology, and founders funds. Neurotez has also had good traction by a few venture capitalist groups and Nikolaos said he anticipates closing a sizeable round in the near future.

“Hopefully, next year’s ‘Dinner to Remember’ will be celebrating this progress,” he said.